Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ARIMIDEX 1 MG

ANASTROZOLE : 1 MG · DIN 02224135 · ASTRAZENECA CANADA INC

Health Canada status: MARKETED

What is ARIMIDEX?

ARIMIDEX 1 MG contains ANASTROZOLE : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02224135, held by ASTRAZENECA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 25-Jan-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is ARIMIDEX used for?

ARIMIDEX (anastrozole) is indicated for: the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Approval is based on superior disease-free survival for ARIMIDEX in comparison to tamoxifen. However, overall survival was not significantly different between the two treatments. hormonal treatment of advanced breast cancer in postmenopausal women.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

What else is ARIMIDEX called?

The same molecule, ANASTROZOLE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
EGISTROZOLLatinCzechia
ALOZEXLatinCzechia
ANAPREXLatinCzechia
ANASTROZOL VIATRISLatinCzechia
ANASTROZOLE COOPERLatinMorocco
Anastrozole GHLatinAustralia
Anastrozole SandozLatinAustralia
ANASTROZOLE-WGRLatinAustralia
ANAYALatinCzechia
APO-AnastrozoleLatinAustralia
ATROCELALatinCzechia
Accord AnastrozoleLatinSouth Africa
ANASTROZOL MYLANLatinCzechia
ANASTROZOL TEVALatinCzechia
Anastrozole PharmacareLatinSaudi Arabia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02224135
Brand nameARIMIDEX
Generic / active ingredientANASTROZOLE : 1 MG
ManufacturerASTRAZENECA CANADA INC
Strength1 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeL02BG03 ANASTROZOLE
AHFS class10:00.00
BiosimilarNo
Health Canada statusMARKETED
Status date25-Jan-2002
Original market date1996-08-30 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02224135
DIN (unpadded, as printed on some documents)2224135
Brand nameARIMIDEX
Active ingredient / INNANASTROZOLE : 1 MG
ATC codeL02BG03
ATC anatomical main groupL — Antineoplastic and immunomodulating agents
ATC therapeutic subgroupL02
AHFS class10:00.00
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderASTRAZENECA CANADA INC

Health Canada approved product monograph (PDF)

How is it stored and handled?

null

How is it supplied?

blister packs of 30 tablets

Which pack is which?

Strength on the label1 MG
Dosage formTABLET
RouteORAL
Packaging as described in the monographblister packs of 30 tablets
Storagenull

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.

Confirm the pack and get a price

What can be used instead?

Other Canadian products sharing ATC code L02BG03 ANASTROZOLE. 18 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
ACH-ANASTROZOLE1 MGTABLETACCORD HEALTHCARE INCMARKETEDDIN 02351218
AG-ANASTROZOLE TABLETS1 MGTABLETANGITA PHARMA INC.MARKETEDDIN 02553686
ANASTROZOLE1 MGTABLETPRO DOC LIMITEEMARKETEDDIN 02395649
ANASTROZOLE1 MGTABLETSANIS HEALTH INCMARKETEDDIN 02442736
ANASTROZOLE1 MGTABLETSIVEM PHARMACEUTICALS ULCMARKETEDDIN 02529904
APO-ANASTROZOLE1 MGTABLETAPOTEX INCMARKETEDDIN 02374420
BIO-ANASTROZOLE1 MGTABLETBIOMED PHARMAMARKETEDDIN 02392488
JAMP ANASTROZOLE TABLETS1 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02540584
JAMP-ANASTROZOLE1 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02339080
MAR-ANASTROZOLE1 MGTABLETMARCAN PHARMACEUTICALS INCMARKETEDDIN 02379562

Who else supplies ANASTROZOLE worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ANASTROZOLE appears in 148 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does ANASTROZOLE cost around the world?

ANASTROZOLE is listed on 13 national price registers Nexara tracks, across 104 pack listings published on 11 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
United Statesacquisition12103 Sep 2026
Czechiamax producer price (ex-factory)91703 Sep 2026
AustriaKVP (Kassenverkaufspreis)121203 Sep 2026
South Africasingle exit price121201 Sep 2026
Australiaex-manufacturer51008 Sep 2026
Hungaryproducer price (ex-factory)7903 Sep 2026
Saudi Arabiapublic7701 Sep 2026
Greeceproducer price (ex-factory)5503 Sep 2026
Luxembourgreimbursement3305 Sep 2026
MoroccoPPV (public price)2305 Sep 2026
United Arab Emiratespublic2231 Aug 2026
Bahrainretail (max)2201 Sep 2026
United Kingdomhospital1131 Aug 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for ARIMIDEX

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02224135. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.